Literature DB >> 25790745

Evaluation of the Utility of in utero Treatment of Twin Anemia-Polycythemia Sequence.

Nicolas Sananès1, Marine Veujoz, Francois Severac, Maël Barthoulot, Nicolas Meyer, Anne-Sophie Weingertner, Monique Kohler, Fernando Guerra, Adrien Gaudineau, Israël Nisand, Romain Favre.   

Abstract

OBJECTIVE: The aim of this study is to evaluate the interest in the in utero treatment of twin anemia-polycythemia sequence (TAPS).
METHODS: The obstetrical and neonatal data on all cases of TAPS followed up in our institution between 2006 and 2013 were reviewed. Statistical analyses were conducted using Bayesian methods.
RESULTS: Twenty cases of TAPS were included. Laser therapy or intrauterine transfusion (IUT) was performed on the donor twin in 9 cases. Eleven cases were included in the 'nontreated' group (managed expectantly or diagnosed at birth). The gestational age at diagnosis was lower in the group with treated TAPS [difference (diff) = -22.20 days (-57.13, 14.28), probability (Pr) (diff >0) = 10.6%]. The rate of preterm premature rupture of membranes was higher in the group with treated TAPS [diff = 22.5% (-14, 57), Pr (diff >0) = 89%], but overall mortality was similar. The interval between diagnosis and delivery was longer [diff = 44.37 days (9.41, 77.90), Pr (diff >0) = 99.2%], the TAPS resolution rate was higher [diff = 49.9% (12, 81), Pr (diff >0) = 99.4%], and the neonatal transfusion rate was lower [diff = -30.5% (-60, 0), Pr (diff >0) = 2.6%] in the treated group.
CONCLUSION: In utero treatment for TAPS is associated with a higher resolution rate of TAPS and a longer time between diagnosis and birth, but overall mortality is the same as with expectant management.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25790745     DOI: 10.1159/000380822

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  1 in total

1.  Treatment and outcome of 370 cases with spontaneous or post-laser twin anemia-polycythemia sequence managed in 17 fetal therapy centers.

Authors:  L S A Tollenaar; F Slaghekke; L Lewi; Y Ville; M Lanna; A Weingertner; G Ryan; S Arévalo; A Khalil; C O Brock; P Klaritsch; K Hecher; G Gardener; E Bevilacqua; K V Kostyukov; M O Bahtiyar; M D Kilby; E Tiblad; D Oepkes; E Lopriore
Journal:  Ultrasound Obstet Gynecol       Date:  2020-09       Impact factor: 7.299

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.